Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$RONN Motor Group, Inc. is a global zero-emission Hydrogen Fuel Cell automaker (FCV). https://ronnmotorgroup.com/visions
$TREIF Treatment.com AI Inc. offers investors a chance to participate in both the healthcare sector — a sector that makes up 11% of our GDP — and the medical AI space, one of the fastest-growing fields around. Speak with your trusted investment advisor to see if a potential high-growth medical AI company like TRUE makes sense for your portfolio.
$TREIF CSE : $TRUE Treatment.com AI Inc.'s AI Medical Information Support Platform Uses in the Objective Structured Clinical Examination
https://www.marketscreener.com/quote/stock/TREATMENT-COM-AI-INC-121607440/news/Treatment-com-AI-Inc-s-AI-Medical-Information-Support-Platform-Uses-in-the-Objective-Structured-Cli-46277030/
$TWOH Two Hands Corporation is a food distribution Company serving food service customers with digital enabled logistics capabilities. The Company is listed on the OTC and CSE under stock symbol TWOH
TMC could go to 59 or 100 bucks. Do some DD.
$AVRW: Avenir Wellness Solutions has never been in a better position to capitalize on the high intrinsic value of our unique and proprietary skin care formulations. With 15 patents under our control, the highly positive reviews Seratopical DNA Complex is receiving, and more new products in development, 2024 is set up to be a growth year for the Company. We look forward to keeping our shareholders informed of our progress, developments and milestones as we move forward.
Sincerely,
Nancy Duitch, CEO
Feb. 13th News Link:
https://finance.yahoo.com/news/avenir-wellness-solutions-issues-2024-140000098.html
Stallion Uranium $STLNF - Uranium Exploration Company Focused In The Athabasca Basin, Drills Being Mobilized https://www.reddit.com/r/PennyStocksWatch/comments/1bfhu5q/stallion_uranium_stlnf_uranium_exploration/
CEO.CA caught up with Drew Zimmerman, CEO of Stallion Uranium $STUD | OTCQB: $STLNF to discuss the land package they’ve put together and the latest expansion, exploration plans, and differentiating themselves from other Athabasca players.
$AURI --SCAM ALERT...see the board
$TWOH Two Hands Corporation: Elevating Canada's Micro Merchant Wholesaler Landscape https://finance.yahoo.com/news/two-hands-corporation-elevating-canadas-130000053.html
$AURI Token Listing and Partnership With a Top 100 CoinMarketcap Exchange https://www.reddit.com/r/BreakoutStocks/comments/1bdzak7/auri_token_listing_and_partnership_with_a_top_100/
#IFBC $IFBC Dino Luzzi Energy Drink and King #Esport Set to Ignite the Gaming Scene at XMAS COMICS #ESPORTS PARTNERSHIP ENERGIZING DINO LUZZI’S INFLUENCE https://finance.yahoo.com/news/dino-luzzi-energy-drink-king-140000045.html
#IFBC $IFBC go out and get @DinoLuzzi Energy drink today. Better than redbull!! Also publicly traded in the #OTCMarkets https://amazon.com/Dino-Luzzi-Energy-Drink-Count/dp/B09K7Y5DG7/ref=mp_s_a_1_3?crid=3UN1C4GYG7J7C&dib=eyJ2IjoiMSJ9.C6gywbI76WpH-JDN9smYMM19f3yatXKfLyftKj_Y7fc.1BJ3N-mJfAFRwkftCh9K8IF162BApw9nMLjzK_IFuyk&dib_tag=se&keywords=dino+luzzi+energy+drink&qid=1709932292&sprefix=%2Caps%2C70&sr=8-3
$STUD | $STLNF Stallion Uranium CEO Drew Zimmerman's webinar with Red Cloud Financial Services where he discussed Stallion's #exploration of over 3,000 sq/km in the Athabasca Basin.
$TWOH, DEBT FREE AND READY TO MINGLE… https://twohandsgroup.com/blog/twoh-debt-free
Discover 2024's #1 Uranium Stock Pick - Stallion Uranium Corp (TSXV: STUD, OTCQB: $STLNF)!
$TWOH — SEIZING OPPORTUNITY AMIDST CHALLENGES: HOW TWO HANDS GROUP (TWOH) IS NAVIGATING RISING FOOD PRICES WITH STRATEGIC ACQUISITIONS
https://twohandsgroup.com/blog/twoh-seizing-opportunity
Italian Food and Beverage Corporation (OTC: $IFBC) is the owner and direct importer of Dino Luzzi Energy Drink, a premium, FDA-approved beverage crafted in Italy and imported to the U.S. In 2022, it made a strategic move to expand its presence in Italy by acquiring 51% of Can International to increase our revenue and further establish its brand in Spain and Switzerland. Key Investment Factors
Growing – Dino Luzzi grew revenues from $38,137 in 2021 to $128,430 in 2022. That’s a 238% increase YoY. This shows the product is in demand, and that demand is growing.
Taste – Dino Luzzi beats out the big guys in blind taste tests. That’s no small feat. While brand recognition remains strong
Expansion Plans – IFBC has developed a significant prime retail space in Western Beef, a New-York based grocer. With 22 warehouse style stores and locations across the Northeastern US (and a few Florida outlets), Dino Luzzi has plenty of shelves to grow into. Additionally, the company has recently partnered with Key Food Fresh and Iavarone Bros. Made in Italy, IFBC’s Energy Drink sets itself apart from the competition by being light, crisp, smooth and refreshing. Most of all, No Metallic After-taste. https://microcaps.com/a-ground-floor-opportunity-in-a-growing-energy-drink-company/
BestGrowthStocks.Com Issues Comprehensive Analysis of IonQ Inc $IONQ
click here>>> https://bit.ly/3Iypkc2
News just issued on $IONQ - BestGrowthStocks.Com Issues Comprehensive Analysis of IonQ Inc
Extensive comprehensive analysis of IonQ’s financial results, potential catalysts, share structure, cash position, quantum computing and AI synergies and much more. Click here>>> https://www.nasdaq.com/press-release/bestgrowthstocks.com-issues-comprehensive-analysis-of-ionq-inc-2024-03-11
NEW YORK, NY / NewsDirect / March 11th, 2024 / Best Growth Stocks, a leading independent equity research and corporate access firm focused on finding and reporting on the best growth stocks utilizing exclusive ai-assisted research recently issued a comprehensive analysis of Petros Pharmaceuticals Inc a company focused on expanding consumer access to medication through over-the-counter (OTC) drug development programs.
Access this full analysis free: https://bit.ly/43axdxO
News just issued on $PTPI - BestGrowthStocks.Com Issues Comprehensive Analysis of Petros Pharmaceuticals Inc
Extensive comprehensive analysis of Petros Pharma’s potential catalysts, share structure, potential outcomes from the FDA decision for STENDRA® (avanafil), and much more. Click here>>> https://www.nasdaq.com/press-release/bestgrowthstocks.com-issues-comprehensive-analysis-of-petros-pharmaceuticals-inc-2024
$LBRG through its subsidiary Growhouse Nutraceuticals Ltd., is actively bolstering its revenue with strategic acquisitions in the health and wellness domain. https://finance.yahoo.com/news/ladybug-announces-acquisition-e-commerce-121500825.html
$CBDW -- March will see 1606 Corp. focusing on growth through strategic partnerships, innovation in product development, and the continued advancement of our technology. https://finance.yahoo.com/news/1606-corp-recaps-major-accomplishments-133000801.html
$LBRG Rebrands as Ladybug NutraTech and Positions Growhouse Nutraceuticals for Strong Growth in 2024 https://finance.yahoo.com/news/ladybug-group-inc-rebrands-ladybug-121500618.html
$CBDW 1606 Corp. Announces AI ChatBot Product Development for Financial Industry https://fox16.com/business/press-releases/accesswire/839256/1606-corp-announces-ai-chatbot-product-development-for-financial-industry/
Crypto #JAM .0026709 GEOJAM going to breakout
$CBDW -- A Bright Future Ahead | With the financial services industry experiencing rapid digital transformation, 1606 Corp.'s introduction of AI-driven chatbots represents a significant leap forward. By providing 24/7 support and utilizing advanced technologies like sentiment analysis and AI predictive capabilities, these chatbots are set to redefine the way financial institutions interact with their customers. https://finance.yahoo.com/news/1606-corp-announces-ai-chatbot-133000500.html
$CBDW Perfect entry zone here @0.03 https://schrts.co/ezqjwGga
$SYNX is proud to announce that it has developed an innovative new product designed for dogs in militaries. https://www.silynxcom.com/silynxcom-unveils-groundbreaking-headset-for-military-dogs-offering-unparalleled-protection-and-communication/
Ladybug Resource Group, Inc. $LBRG Rebrands as Ladybug NutraTech and Positions Growhouse Nutraceuticals for Strong Growth in 2024 https://www.reddit.com/r/BreakoutStocks/comments/1b8x70a/ladybug_resource_group_inc_lbrg_rebrands_as/
Silynxcom Scores Significant Add-On Deals $SYNX
$LBRG Rebrands as Ladybug NutraTech and Positions Growhouse Nutraceuticals for Strong Growth in 2024
https://finance.yahoo.com/news/ladybug-group-inc-rebrands-ladybug-121500618.html
$LBRG Ladybug Announces Acquisition of E-Commerce Generating $2.4 Million Annual Revenue
https://finance.yahoo.com/news/ladybug-announces-acquisition-e-commerce-121500825.html
$SYNX Silynx provides protection for our canine warriors.
Silynx provides protection for our canine warriors. $SYNX #k9hearingprotection #fourleggedwarriors #bestinclass 🐾🐾 pic.twitter.com/meaZrNBirX
— Silynx Communications (@silynxcomm) March 5, 2024
$$$???»»»STRC«««???$$$
THE NEXT HUGE WINNER!
$NRXP News: NRx Pharmaceuticals (NASDAQ: NRXP) Announces Last Patient, Last Visit in its Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression
Marks a major step in the development of what could be the first drug approved for Suicidal Bipolar Depression
The study database is being cleaned and locked; statistical analysis and top-line data to follow shortly thereafter
Study maintained 95% concordance rate between study sites and central raters on primary endpoint. No unexpected Serious Adverse Events were reported.
Positive data and FDA comment would trigger the next $4 million milestone payment from partners Alvogen and Lotus and their assumption of development costs; agreement provides for up to $329 million in milestone payments and a royalty on Net Sales in the mid-teens
RADNOR, Pa., March 4, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that the 74th and last evaluable patient has completed their day 42 visit in its Phase 2b/3 study of NRX-101, the Company's patented combination of the NMDA antagonist D-cycloserine and lurasidone, in Suicidal Treatment Resistant Bipolar Depression. The database is being cleaned, finalized, and locked; statistical analysis will then be performed, with top-line data to follow shortly thereafter. As previously disclosed, positive data from this trial triggers a milestone payment from Alvogen. Alvogen will then be responsible for further development and commercialization costs for this program.
NRX-101 has been awarded Breakthrough Therapy Designation, Fast Track Designation, a Biomarker Letter of Support, and a Special Protocol Agreement by the FDA for treatment of suicidal bipolar depression. It is the only oral medication to have demonstrated reduced suicidal ideation in patients with bipolar depression, a lethal disease that claims the lives of one in five who live with it.
"This is the first clinical trial, to the company's knowledge, conducted among patients with suicidal bipolar depression in the outpatient setting. Our previous trial measured the ability of NRX-101 to maintain the anti-depressant and anti-suicidal effect of ketamine administered in the hospital setting. These patients, whose clinical need is urgent and extraordinary have routinely been excluded from the clinical trials of all previously-known anti-depressant drugs. said Dr. Jonathan Javitt, Founder, Chairman and Chief Scientist of NRx Pharmaceuticals. Although there were patients whose depression worsened and required hospitalization (we don't yet know whether they were on NRX-101 or comparator), patient safety was maintained, and no trial participant suffered a serious unexpected adverse outcome. Our thanks go out to our investigators, clinics, partners and, most importantly, our amazing patients and their families for seeing this study through to this important milestone," "
The Phase 2b/3 trial (www.clinicaltrials.gov NCT 03395392) is a randomized, prospective, multicenter, double-blind study comparing NRX-101 to lurasidone over six weeks. The Principal Investigator is Prof. Andrew Nierenberg of Harvard Massachusetts General Hospital. The primary efficacy endpoint is reduction in depression as measured on the MADRS scale and the secondary endpoint is reduction of suicidal ideation as measured by the Clinical Global Impression Suicidality Scale (CGI-SS). As previously disclosed, treatment compliance and concordance of local raters to central raters scores was in excess of 94%, well above the industry standard that is normally seen in CNS trials.
Top-line results are expected around the end of this quarter.
About NRx Pharmaceuticals
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx has partnered with Alvogen and Lotus around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRx has recently announced plans to submit a New Drug Application for HTX-100 (IV ketamine), through Hope Therapeutics, in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
About HOPE Therapeutics, Inc.
HOPE Therapeutics, Inc. (www.hopetherapeutics.com) is a Specialty Pharmaceutical Company, wholly-owned by NRX Pharmaceuticals focused on development and marketing of an FDA-approved form of intravenous ketamine for the treatment of acute suicidality and depression together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.
Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the proposed public offering and the timing and the use of the proceeds from the offering. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy and liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.
https://c212.net/c/img/favicon.png?sn=CL51263&sd=2024-03-04 View original content to download multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-nasdaq-nrxp-announces-last-patient-last-visit-in-its-phase-2b3-trial-of-nrx-101-in-suicidal-treatment-resistant-bipolar-depression-302078041.html
SOURCE NRx Pharmaceuticals, Inc.
$DFCO Dalrada CEO's Plan to Dominate the Global Heat Pump Market
PRESS RELEASE $CBDW 1606 Corp
*** PRESS RELEASE *** 1606 Corp. Announces AI ChatBot Product Development for Financial Industry | SEATTLE, WA / ACCESSWIRE / March 5, 2024 / 1606 Corp. (OTC PINK: $CBDW) (the "Company"), in a strategic move to revolutionize customer engagement and expand its market reach, 1606… pic.twitter.com/UmaPF3oZYi
— CBDW.ai | A Brand by 1606 Corp (@CBDWInc) March 5, 2024
Silynxcom $SYNX Unveils Dual-Use Headset for Military Dogs https://reddit.com/r/stockstobuytoday/comments/1b75m1g/silynxcom_synx_unveils_dualuse_headset_for/
#BreakingNews: $LBRG Ladybug Announces Acquisition of E-Commerce Generating $2.4 Million Annual Revenue
https://finance.yahoo.com/news/ladybug-announces-acquisition-e-commerce-121500825.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr
$LBRG the parent company of Growhouse Nutraceuticals, is pleased to announce its strategic rebranding as Ladybug NutraTech. https://finance.yahoo.com/news/ladybug-group-inc-rebrands-ladybug-121500618.html
$SYNX Silynxcom Received $550,000 in Orders from Israel Defense and Israeli Police Forces Since Beginning of Year https://finance.yahoo.com/news/silynxcom-received-550-000-orders-142800035.html
Best Growth Stocks Takes a Deep Dive into Potential Fisker Nissan Deal - https://www.nasdaq.com/press-release/bestgrowthstocks.com-takes-a-deep-dive-into-potential-fisker-nissan-deal-2024-03-03
$LBRG is delighted to announce that Bilal Bhamji has joined our company as Chief Financial Officer (CFO), and James Kurko has come on board as a Director. https://finance.yahoo.com/news/ladybug-group-inc-announces-addition-121500907.html
Filing Delayed, but Potential High! 🚀$EDXC may be ready to bounce back! 📈🚀 Keep an eye on this sleeper! 💎
https://finance.yahoo.com/news/endexx-corporation-announces-transition-auditor-140000342.html
$CBDW 1606 Corp. Recaps Major Accomplishments in February & Provides Outlook For March https://finance.yahoo.com/news/1606-corp-recaps-major-accomplishments-133000801.html
$TWOH Two Hands Group stands at the forefront of transforming the food distribution landscape in Canada by leveraging a meticulously crafted playbook for acquiring food merchants with revenues between $1.5M and 5 million dollars. https://twohandsgroup.com/blog/strategic-expansion-twoh-acquisition-playbook
$SYNX SILYNXCOM DELIVERS $280,000 REPEAT ORDER FROM MILITARY CUSTOMER
https://fragoutmag.com/silynxcom-delivers-280000-repeat-order-from-military-customer/
Followers
|
945
|
Posters
|
|
Posts (Today)
|
1
|
Posts (Total)
|
30325
|
Created
|
06/17/11
|
Type
|
Free
|
Moderator ~ Blue ~ | |||
Assistants doogdilinger balamidas MOMO vantillian CHIEF-RISES-ABOVE |
Posts Today
|
1
|
Posts (Total)
|
30325
|
Posters
|
|
Moderator
|
|
Assistants
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |